COMP <GO>
TARS vs LLY // REVENUE GROWTH (YOY)
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TARS 2
— LLY 8
▲ REVENUE GROWTH (YOY) LEADER: TARS
LAST: $74.85 (+0.88%) • MKT CAP: $3.66B
revenue-growth
146.70%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | 32.36% | -56.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | 2.30% | -2.91 | LLY | /fcf-yield <GO> |
| Operating Margin | -15.70% | 40.21% | -55.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | -14.60% | 31.90% | -46.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 146.70% | 45.51% | +101.19 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | 9.29 | +0.90 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.4 | 66.6 | -13.20 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.66B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | LLY REV | TARS GROSS % | LLY GROSS % | TARS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $65.18B | — | 83.0% | -$22.3M | $16.81B |
| FY 2024 | $183.0M | $45.04B | — | 81.3% | -$84.6M | $8.82B |
| FY 2023 | $17.4M | $34.12B | — | 79.3% | -$117.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
LLY // BETA 0.51